bioAffinity Technologies (NASDAQ:BIAF) Shares Down 7.5% – Here’s What Happened

Shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) traded down 7.5% during trading on Monday . The stock traded as low as $1.57 and last traded at $1.60. 206,736 shares were traded during trading, an increase of 3% from the average session volume of 199,892 shares. The stock had previously closed at $1.73.

Analyst Ratings Changes

Several analysts recently commented on the stock. Wall Street Zen cut shares of bioAffinity Technologies from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings cut shares of bioAffinity Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

bioAffinity Technologies Stock Performance

The company has a debt-to-equity ratio of 0.15, a current ratio of 1.36 and a quick ratio of 1.34. The firm has a market capitalization of $7.25 million, a price-to-earnings ratio of -0.14 and a beta of -1.33. The firm’s fifty day moving average is $2.46 and its 200 day moving average is $1.82.

bioAffinity Technologies (NASDAQ:BIAF) last posted its earnings results on Friday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.40) by $1.59. The firm had revenue of $1.35 million during the quarter, compared to analysts’ expectations of $1.48 million. bioAffinity Technologies had a negative net margin of 280.53% and a negative return on equity of 285.75%.

Institutional Trading of bioAffinity Technologies

A number of institutional investors have recently added to or reduced their stakes in the business. J. Safra Sarasin Holding AG acquired a new stake in bioAffinity Technologies in the first quarter valued at approximately $164,000. Geode Capital Management LLC acquired a new stake in bioAffinity Technologies in the fourth quarter valued at approximately $36,000. Scientech Research LLC acquired a new stake in bioAffinity Technologies in the third quarter valued at approximately $49,000. Finally, Sabby Management LLC acquired a new stake in bioAffinity Technologies in the third quarter valued at approximately $719,000. 1.64% of the stock is currently owned by institutional investors and hedge funds.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.